Anzeige
❌
Mehr »
Montag, 05.10.2026 - Börsentäglich über 12.000 News
Die Jobs, die keine KI der Welt ersetzen kann - und das Unternehmen dahinter
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker-Symbol: 2I9
Frankfurt
02.10.26 | 20:15
0,000 Euro
0,00 % 0,000
1-Jahres-Chart
KDVENTURES AB Chart 1 Jahr
5-Tage-Chart
KDVENTURES AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0000,05204.10.

Aktuelle News zur KDVENTURES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiKDventures AB: KDventures' portfolio company AnaCardio raises EUR 62.5 million in Series B financing150STOCKHOLM, Sweden, September 30, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company AnaCardio has entered into a EUR 62.5 million Series B financing. The financing...
► Artikel lesen
15.09.KDventures AB: KDventures' portfolio company Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis172STOCKHOLM, Sweden, September 15, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition has reported that the last patient has completed the final...
► Artikel lesen
07.09.KDventures AB: KDventures' portfolio company Umecrine Cognition receives two Notices of Allowance in the US for second-generation GAMSA compounds432STOCKHOLM, Sweden, September 7, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition has received two Notices of Allowance from the United States...
► Artikel lesen
28.08.KDventures AB: Interim Report - January-June 2026234STOCKHOLM - 28 Augusti 2026. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Interim Report January-June 2026. The full report is available on the Company's website. "Following the acquisition...
► Artikel lesen
03.08.KDventures AB: KDventures' portfolio company Umecrine Cognition enrolls last patient in ongoing Phase 1b/2a study187STOCKHOLM, Sweden, August 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition has enrolled the last patient in the ongoing Phase 1b/2a study...
► Artikel lesen
12.05.KDventures AB: KDventures' Annual General Meeting 2026297STOCKHOLM, SWEDEN - May 12, 2026. KDventures AB (publ) ("KDventures" or the "Company") held the Annual General Meeting on May 12, 2026. The shareholders have had the right to exercise their voting rights...
► Artikel lesen
KDVENTURES Aktie jetzt für 0€ handeln
30.04.KDventures AB: Interim Report - January-March 2026325STOCKHOLM - 30 April 2026. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Interim Report January-March 2026. The full report is available on the Company's website. "We started 2026 by strengthening...
► Artikel lesen
09.04.KDventures AB: KDventures' portfolio company SVF Vaccines partners with Touchlight to accelerate SVF-001 toward clinical development287STOCKHOLM, Sweden, April 9, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company SVF Vaccines has entered into a collaboration with Touchlight, a biotechnology company...
► Artikel lesen
11.03.KDventures AB: KDventures' portfolio company AnaCardio extends IP protection for AC01 until the 2040s with new US patent approval299STOCKHOLM, SWEDEN March 11, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company AnaCardio has received approval for a US patent covering the use of AC01 for the treatment...
► Artikel lesen
03.03.KDventures AB: KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS499STOCKHOLM, Sweden, March 3, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome...
► Artikel lesen
24.02.KDventures AB: KDventures's portfolio company SVF Vaccines announces that the intended merger with Novakand Pharma will not be carried out following negative decision from Nasdaq522STOCKHOLM, Sweden, February 24, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed...
► Artikel lesen
13.02.KDventures AB: Year-end Report - January-December 2025361STOCKHOLM - 13 February 2025. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Year-end Report January-December 2025. The full report is available on the Company's website. "A stronger financial...
► Artikel lesen
12.02.KDventures AB (publ): KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue389NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
► Artikel lesen
10.02.KDventures AB (publ): KDventures' portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer431STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition...
► Artikel lesen
09.02.Change of issuer name and symbol for Karolinska Development AB466As from February 10, 2026, Karolinska Development AB will change issuer name and symbol. Old issuer name: Karolinska Development AB New issuer name: KDventures AB Old symbol: KDEV New symbol: KDV ISIN...
► Artikel lesen
06.02.Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement381STOCKHOLM, Sweden, February 6, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has entered into a reverse acquisition agreement with Novakand...
► Artikel lesen
28.01.Karolinska Development AB: Karolinska Development AB (publ) announces the outcome of the rights issue and change of the company name to KDventures AB488NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
► Artikel lesen
23.01.Karolinska Development AB (publ): Karolinska Development AB receives additional guarantee commitments in ongoing rights issue792NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
► Artikel lesen
21.01.Karolinska Development AB (publ): Karolinska Development's portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparin373STOCKHOLM, SWEDEN - January 21, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has signed a binding term sheet with Exeltis, a global Women's...
► Artikel lesen
12.01.Listing of subscription rights and paid subscription shares of Karolinska Development AB449With effect from January 13, 2026, the subscription rights of Karolinska Development AB will be traded on the list for Equity rights. Trading will continue up until and including January 22, 2026. ...
► Artikel lesen
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1